EMA Authorised: Ultomiris (ravulizumab) — Alexion Europe SAS

View source ↗

Summary

The European Medicines Agency authorised Ultomiris (ravulizumab) for paroxysmal nocturnal hemoglobinuria, under the responsibility of Alexion Europe SAS.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• ULTOMIRIS (ravulizumab)

Snippet

Status: Authorised. Therapeutic area: Hemoglobinuria, Paroxysmal. MAH: Alexion Europe SAS. Decision date: 11/09/2025